8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Association of NLRP1 Coding Polymorphism with Lung Function and Serum IL-1β Concentration in Patients Diagnosed with Chronic Obstructive Pulmonary Disease (COPD)

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Chronic obstructive pulmonary disease (COPD) is a chronic disease characterized by a progressive decline in lung function due to airflow limitation, mainly related to IL-1β-induced inflammation. We have hypothesized that single nucleotide polymorphisms (SNPs) in NLRP genes, coding for key regulators of IL-1β, are associated with pathogenesis and clinical phenotypes of COPD. We recruited 704 COPD individuals and 1238 healthy controls for this study. Twenty non-synonymous SNPs in 10 different NLRP genes were genotyped. Genetic associations were estimated using logistic regression, adjusting for age, gender, and smoking history. The impact of genotypes on patients’ overall survival was analyzed with the Kaplan–Meier method with the log-rank test. Serum IL-1β concentration was determined by high sensitivity assay and expression analysis was done by RT-PCR. Decreased lung function, measured by a forced expiratory volume in 1 s (FEV 1% predicted), was significantly associated with the minor allele genotypes (AT + TT) of NLRP1 rs12150220 ( p = 0.0002). The same rs12150220 genotypes exhibited a higher level of serum IL-1β compared to the AA genotype ( p = 0.027) in COPD patients. NLRP8 rs306481 minor allele genotypes (AG + AA) were more common in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) definition of group A ( p = 0.0083). Polymorphisms in NLRP1 (rs12150220; OR = 0.55, p = 0.03) and NLRP4 (rs12462372; OR = 0.36, p = 0.03) were only nominally associated with COPD risk. In conclusion, coding polymorphisms in NLRP1 rs12150220 show an association with COPD disease severity, indicating that the fine-tuning of the NLRP1 inflammasome could be important in maintaining lung tissue integrity and treating the chronic inflammation of airways.

          Related collections

          Most cited references27

          • Record: found
          • Abstract: found
          • Article: not found

          New insights into the immunology of chronic obstructive pulmonary disease.

          Chronic obstructive pulmonary disease (COPD) is a heterogeneous syndrome associated with abnormal inflammatory immune responses of the lung to noxious particles and gases. Cigarette smoke activates innate immune cells such as epithelial cells and macrophages by triggering pattern recognition receptors, either directly or indirectly via the release of damage-associated molecular patterns from stressed or dying cells. Activated dendritic cells induce adaptive immune responses encompassing T helper (Th1 and Th17) CD4+ T cells, CD8+ cytotoxicity, and B-cell responses, which lead to the development of lymphoid follicles on chronic inflammation. Viral and bacterial infections not only cause acute exacerbations of COPD, but also amplify and perpetuate chronic inflammation in stable COPD via pathogen-associated molecular patterns. We discuss the role of autoimmunity (autoantibodies), remodelling, extracellular matrix-derived fragments, impaired innate lung defences, oxidative stress, hypoxia, and dysregulation of microRNAs in the persistence of the pulmonary inflammation despite smoking cessation. Copyright © 2011 Elsevier Ltd. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Mortality in COPD: Role of comorbidities.

            Chronic obstructive pulmonary disease (COPD) represents an increasing burden throughout the world. COPD-related mortality is probably underestimated because of the difficulties associated with identifying the precise cause of death. Respiratory failure is considered the major cause of death in advanced COPD. Comorbidities such as cardiovascular disease and lung cancer are also major causes and, in mild-to-moderate COPD, are the leading causes of mortality. The links between COPD and these conditions are not fully understood. However, a link through the inflammation pathway has been suggested, as persistent low-grade pulmonary and systemic inflammation, both known risk factors for cardiovascular disease and cancer, are present in COPD independent of cigarette smoking. Lung-specific measurements, such as forced expiratory volume in one second (FEV(1)), predict mortality in COPD and in the general population. However, composite tools, such as health-status measurements (e.g. St George's Respiratory Questionnaire) and the BODE index, which incorporates Body mass index, lung function (airflow Obstruction), Dyspnoea and Exercise capacity, predict mortality better than FEV(1) alone. These multidimensional tools may be more valuable because, unlike predictive approaches based on single parameters, they can reflect the range of comorbidities and the complexity of underlying mechanisms associated with COPD. The current paper reviews the role of comorbidities in chronic obstructive pulmonary disease mortality, the putative underlying pathogenic link between chronic obstructive pulmonary disease and comorbid conditions (i.e. inflammation), and the tools used to predict chronic obstructive pulmonary disease mortality.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Comorbidities in chronic obstructive pulmonary disease.

              Comorbidities such as cardiac disease, diabetes mellitus, hypertension, osteoporosis, and psychological disorders are commonly reported in patients with chronic obstructive pulmonary disease (COPD) but with great variability in reported prevalence. Tobacco smoking is a risk factor for many of these comorbidities as well as for COPD, making it difficult to draw conclusions about the relationship between COPD and these comorbidities. However, recent large epidemiologic studies have confirmed the independent detrimental effects of these comorbidities on patients with COPD. On the other hand, many of these comorbidities are now considered to be part of the commonly prevalent nonpulmonary sequelae of COPD that are relevant not only to the understanding of the real burden of COPD but also to the development of effective management strategies.
                Bookmark

                Author and article information

                Journal
                Genes (Basel)
                Genes (Basel)
                genes
                Genes
                MDPI
                2073-4425
                09 October 2019
                October 2019
                : 10
                : 10
                : 783
                Affiliations
                [1 ]Ruđer Bošković Institute, Division of Molecular Medicine, 10 000 Zagreb, Croatia; Petar.Ozretic@ 123456irb.hr (P.O.); Maja.Sutic@ 123456irb.hr (M.Š.); Matea.Kurtovic@ 123456irb.hr (M.K.); Oliver.Vugrek@ 123456irb.hr (O.V.)
                [2 ]Division of Molecular Genetic Epidemiology, DKFZ, 69 120 Heidelberg, Germany; miguelisifi@ 123456yahoo.com (M.I.d.S.F.); c.catalano@ 123456dkfz-heidelberg.de (C.C.)
                [3 ]Department for Respiratory Diseases Jordanovac, University of Zagreb School of Medicine, University Hospital Centre Zagreb, 10 000 Zagreb, Croatia; isokolovic2@ 123456gmail.com (I.S.); adugac71@ 123456gmail.com (A.V.-D.); gordana.bubanovic@ 123456kbc-zagreb.hr (G.B.); sanja.popovic.grle@ 123456kbc-zagreb.hr (S.P.-G.); miroslav.samarzija@ 123456gmail.com (M.S.); marko.jakopovic@ 123456kbc-zagreb.hr (M.J.)
                [4 ]Josip Juraj Strossmayer University of Osijek, School of Medicine, 31 000 Osijek, Croatia; sanda.cincar@ 123456gmail.com
                [5 ]Department of Pulmology, Universitiy Hospital Center Osijek, 31 000 Osijek, Croatia
                [6 ]Croatian Institute of Transfusion Medicine, 10 000 Zagreb, Croatia; irena.jukic@ 123456hztm.hr
                [7 ]Department of Medical Biochemistry and Hematology, Faculty of Pharmacy and Biochemistry, University of Zagreb, 10 000 Zagreb, Croatia; ladarumora@ 123456gmail.com
                [8 ]Fidelta d.o.o., Prilaz baruna Filipovića 29, 10 000 Zagreb, Croatia; Martina.Bosnar@ 123456glpg.com
                [9 ]Department of Internal Medicine V-Pulmonology, Allergology, Intensive Care Medicine, Saarland University, 66 424 Homburg, Germany; Robert.Bals@ 123456uks.eu
                Author notes
                [* ]Correspondence: A.Foersti@ 123456dkfz-heidelberg.de (A.F.); jknezev@ 123456irb.hr (J.K.); Tel.: +385-1-4560-964 (J.K.)
                [†]

                These authors contributed equally.

                [‡]

                These authors share senior authorship.

                Author information
                https://orcid.org/0000-0001-9757-6636
                https://orcid.org/0000-0001-5210-9196
                https://orcid.org/0000-0002-8482-8889
                https://orcid.org/0000-0002-9857-4728
                https://orcid.org/0000-0002-3152-3563
                Article
                genes-10-00783
                10.3390/genes10100783
                6826440
                31601004
                162e56c4-6c5a-4fd5-9a5b-402eb9498a31
                © 2019 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 13 July 2019
                : 01 October 2019
                Categories
                Article

                copd,nlrp,polymorphism,fev1,fev1/fvc,gold,serum il-1β
                copd, nlrp, polymorphism, fev1, fev1/fvc, gold, serum il-1β

                Comments

                Comment on this article